Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study

Pomalidomide Plus Low-Dose Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients: Results of the Real-World “POWERFUL” Study

The “POWERFUL” multicenter, retrospective, and prospective study investigated the effectiveness of pomalidomide plus low-dose dexamethasone (POM/LoDex) therapy in relapsed/refractory multiple myeloma in routine care in Greece. Ninety-nine eligible adult patients treated with POM/LoDex according to t...

Full description

Bibliographic Details
Main Authors: Evangelos Terpos, Panagiotis Repousis, Chrysavgi Lalayanni, Evdoxia Hatjiharissi, Theodora Assimakopoulou, Georgios Vassilopoulos, Anastasia Pouli, Emmanouil Spanoudakis, Eurydiki Michalis, Gerassimos Pangalis, Ioannis Ntanasis-Stathopoulos, Christos Poziopoulos, Marie-Christine Kyrtsonis, Vasiliki Pappa, Argiris Symeonidis, Christos Georgopoulos, Panagiotis M. Zikos, Maria Gavriatopoulou, Helen A. Papadaki, Magdalini Dadakaridou, Kiki Karvounis-Marolachakis, Eirini Katodritou
Format: Article
Language:English
Published: MDPI AG 2021-04-01
Series:Journal of Clinical Medicine
Subjects:
duration of response
lenalidomide
multiple myeloma
pomalidomide
PFS
ORR
Online Access:https://www.mdpi.com/2077-0383/10/7/1509

Internet

https://www.mdpi.com/2077-0383/10/7/1509

Similar Items